Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at support@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support support@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support support@hstalks.com
We hope you have enjoyed this limited-length demo talk
This is a limited length demo talk; you may
login
or review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk objectives
- Systemic Lupus Erythematosus (SLE)
- SLE images
- Pathogenesis of inflammation in SLE
- SLE – complement and disease activity
- Difficulties in complement assays
- Complement and disease activity
- Complement activation products: examples
- Complement activation products: do they help?
- The clinical evidence doesn’t quite fit
- Complement deficiency and SLE
- Complement deficiency and SLE (illustration)
- Complement and SLE: paradox
- Complement and lupus pathogenesis
- “Waste disposal” hypothesis
- Mechanisms in C1q regulation of autoimmunity
- C1q binding and dying cells disposal
- C3-dependent clearance of apoptotic cells
- Defective removal of dying cells leads to SLE
- Complement deficiency
- Complement and SLE: just an old story?
- Complement and SLE: ITGAM
- CD11b/CD18 (Mac-1/CR3)
- Cell surface expression of CD11
- Phagocytosis of hiC3b-coated beads by cells
- Complement and SLE: conclusions
- ‘SLE paradox'
- Anti-C1q antibodies and SLE
- Anti-C1q antibodies: detection
- Anti-C1q Abs: what do they recognise?
- Anti-C1q antibodies and SLE
- Are anti-C1q antibodies truly pathogenic?
- Administration of anti-C1q mAb to naïve mice
- Anti-C1q mAb & anti-GBM pretreated mice
- Anti-C1q antibodies and SLE (illustration)
- The development of anti-C1q antibodies in SLE
- Complement activation and renal inflammation
- Anti-C1q Abs: conclusions
- Complement and lupus nephritis
- Complement therapeutics
- Eculizumab (anti-C5 Ab) and SLE
- Complement and SLE: conclusions
- Complement and SLE: graphic summary
- Thank you
Topics Covered
- Measurement of complement in lupus
- The role of complement in lupus pathogenesis
- Anti-C1q antibodies (pathogenic or epiphenomenon?)
- Complement therapy in lupus
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Botto, M. (2018, January 31). Complement and lupus [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 18, 2019, from https://hstalks.com/bs/3658/.Publication History
Complement and lupus
Published on January 31, 2018
42 min
Transcript
0:00
My name is Marina Botto.
I'm a Professor of Rheumatology at the Imperial College,
and I'm interested in the role of the complement in systemic lupus erythematosus.
0:14
In these slides, I'm just summarize some of
the key points that I would like to cover today.
First, I will start with a discussion of the value of measuring complement in lupus,
and discuss whether these measurement are clinically helpful.
Then I will briefly discuss the paradoxical role of complement in lupus pathogenesis,
and highlighting the different role of the C1q and C3.
And we'll also mention recent study linking lupus to
some genetic polymorphisms in the complement system to
demonstrate how complement biology is not just an old story.
I would like also to mention the role of
anti-C1q antibodies in the context of this disease.
Finally, I will close by mentioning the potential role
that complement therapy may have in this disease in the future.